These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 320014)

  • 21. Potentiation by metyrosine of thioridazine effects in chronic schizophrenics. A long-term trial using double-blind crossover technique.
    Wålinder J; Skott A; Carlsson A; Roos BE
    Arch Gen Psychiatry; 1976 Apr; 33(4):501-5. PubMed ID: 779704
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Absorption and excretion of thioridazine and mesoridazine in man.
    Charalampous KD; Johnson PC; Estevez V
    Dis Nerv Syst; 1974 Nov; 35(11):494-6. PubMed ID: 17896456
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of the effects of thioridazine and mesoridazine on the QT interval in healthy adults after single oral doses.
    Salih IS; Thanacoody RH; McKay GA; Thomas SH
    Clin Pharmacol Ther; 2007 Nov; 82(5):548-54. PubMed ID: 17410120
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Haloperidol and thioridazine drug levels and clinical response in schizophrenia: comparison of gas-liquid chromatography and radioreceptor drug level assays.
    Smith RC; Baumgartner R; Burd A; Ravichandran GK; Mauldin M
    Psychopharmacol Bull; 1985; 21(1):52-8. PubMed ID: 3983338
    [No Abstract]   [Full Text] [Related]  

  • 25. Serum concentration and elimination from serum of thioridazine in psychiatric patients.
    Axelsson R; Mårtensson E
    Curr Ther Res Clin Exp; 1976 Feb; 19(2):242-65. PubMed ID: 813963
    [No Abstract]   [Full Text] [Related]  

  • 26. Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype.
    von Bahr C; Movin G; Nordin C; Lidén A; Hammarlund-Udenaes M; Hedberg A; Ring H; Sjöqvist F
    Clin Pharmacol Ther; 1991 Mar; 49(3):234-40. PubMed ID: 2007317
    [TBL] [Abstract][Full Text] [Related]  

  • 27. GLC analysis of thioridazine, mesoridazine, and their metabolites.
    Dinovo EC; Gottschalk LA; Nandi BR; Geddes PG
    J Pharm Sci; 1976 May; 65(5):667-9. PubMed ID: 932933
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plasma propranolol levels and their effect on plasma thioridazine and haloperidol concentrations.
    Greendyke RM; Kanter DR
    J Clin Psychopharmacol; 1987 Jun; 7(3):178-82. PubMed ID: 3597804
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Plasma levels of mesoridazine and its metabolites and clinical response in acute schizophrenia after a single intramuscular drug dose.
    Gottschalk LA; Dinovo E; Bierner R
    Psychopharmacol Bull; 1975 Oct; 11(4):33-4. PubMed ID: 812135
    [No Abstract]   [Full Text] [Related]  

  • 30. Serum levels of thioridazine in psychiatric patients and healthy volunteers.
    Mårtensson E; Roos BE
    Eur J Clin Pharmacol; 1973 Oct; 6(3):181-6. PubMed ID: 4762056
    [No Abstract]   [Full Text] [Related]  

  • 31. Serum concentration and protein binding of thioridazine and its metabolites in patients with chronic alcoholism.
    Axelsson R; Mårtensson E; Alling C
    Eur J Clin Pharmacol; 1982 Oct; 23(4):359-63. PubMed ID: 7173306
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Single dose kinetics of thioridazine and its two psychoactive metabolites in healthy humans: a dose proportionality study.
    Chakraborty BS; Midha KK; McKay G; Hawes EM; Hubbard JW; Korchinski ED; Choc MG; Robinson WT
    J Pharm Sci; 1989 Oct; 78(10):796-801. PubMed ID: 2600782
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Thioridazine and its metabolites in post mortem blood, including two stereoisomeric ring sulfoxides.
    Poklis A; Wells CE; Juenge EC
    J Anal Toxicol; 1982; 6(5):250-2. PubMed ID: 7176556
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype.
    Berecz R; de la Rubia A; Dorado P; Fernández-Salguero P; Dahl ML; LLerena A
    Eur J Clin Pharmacol; 2003 May; 59(1):45-50. PubMed ID: 12682803
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combined therapy with thioridazine decreases plasma levels of quetiapine inTaiwanese schizophrenic patients.
    Chang SC; Lu ML; Wang YC; Lin FW; Huang SH; Kuo PH; Ho HO; Wu TH
    Ther Drug Monit; 2012 Jun; 34(3):345-8. PubMed ID: 22569350
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Measurement of thioridazine in blood and urine.
    Ng CH; Crammer JL
    Br J Clin Pharmacol; 1977 Apr; 4(2):173-83. PubMed ID: 16633
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Blood levels of thioridazine and some of its metabolites in psychiatric patients. A preliminary report.
    Buyze G; Egberts PF; Muusze RG; Poslavsky A
    Psychiatr Neurol Neurochir; 1973; 76(3):229-39. PubMed ID: 4725794
    [No Abstract]   [Full Text] [Related]  

  • 38. The pharmacokinetics of some psychoactive drugs and relationships to clinical response.
    Gottschalk LA
    Methods Find Exp Clin Pharmacol; 1985 May; 7(5):275-82. PubMed ID: 3897748
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prophylactic effects of neuroleptics in symptom-free schizophrenics: roles of dopaminergic and noradrenergic blockers.
    Nishikawa T; Tsuda A; Tanaka M; Koga I; Uchida Y
    Biol Psychiatry; 1985 Nov; 20(11):1161-6. PubMed ID: 3902105
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High plasma concentrations of metoclopramide are not detected by radioreceptor assay.
    Stanley M; Wazer D
    Neuropsychobiology; 1983; 10(2-3):108-10. PubMed ID: 6674818
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.